Sorrento Therapeutics

Sorrento Therapeutics completes IgDraSol merger

Wednesday, September 11, 2013 01:31 PM

Sorrento Therapeutics has completed its merger with Igdrasol, a privately-held company focused on the development of cancer therapeutics. Igdrasol shareholders will receive the equivalent of 3,047,968 million shares of Sorrento's common stock. Reflecting Sorrento's recent reverse stock split, and based on the closing share price on Sept. 6, 2013, the transaction is valued at $28.2 million.

More... »

Sorrento Therapeutics licenses Biomiga Diagnostics' drug monitoring device

Wednesday, September 11, 2013 01:26 PM

Sorrento Therapeutics, a publicly-traded, development-stage biopharmaceutical company, has secured an exclusive license for the worldwide rights to Biomiga Diagnostics' proprietary therapeutic drug monitoring (TDM) device for paclitaxel products. The agreement allows Sorrento to utilize the TDM device for the clinical development of individualized dosing regimens of Sorrento's late-stage compound, Cynviloq (paclitaxel polymeric micelle).

More... »

Sorrento, BGN Technologies collaborate on Hepatitis C

Wednesday, July 17, 2013 12:17 PM

Sorrento Therapeutics, a publicly-traded, development-stage biopharmaceutical company, and BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, have entered into an option and license agreement covering several anti-Hepatitis C Virus (HCV) antibody clones identified from patients who have recovered from HCV infections. Sorrento plans to develop these early findings into a potential therapeutic product.

More... »

Sorrento, Igdrasol acquire E.U. distribution rights to Cynviloq from Samyang

Wednesday, May 15, 2013 12:46 PM

Sorrento Therapeutics, a development-stage biopharmaceutical company, and Igdrasol, a developer of personalized paclitaxel, have acquired exclusive distribution rights from Samyang Biopharmaceuticals, a South Korean corporation, to Cynviloq (marketed as Genexol-PMR in South Korea) in the 27 countries of E.U.

More... »

Sorrento Therapeutics acquires rights to produce rIVIG

Wednesday, January 9, 2013 02:33 PM

Sorrento Therapeutics, a development-stage biopharmaceutical company, has acquired worldwide rights that will allow for the application of its antibody library technology for the production of recombinant Intravenous immunoglobulins (rIVIG).

More... »